References

Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer

10.3892/ijo.2022.5378 · 2022 · External reference

A comprehensive review of immune checkpoint inhibitors for cancer treatment

10.1016/j.intimp.2024.113365 · 2024 · External reference

Improving natural killer cell cancer immunotherapy

10.1097/mot.0000000000000243 · 2015 · External reference

Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: a novel strategy from epigenetic dysregulation to clinical therapy

10.3892/ol.2025.15265 · 2025 · External reference

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · 2024 · External reference

Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy

10.3390/cells8080803 · 2019 · External reference

Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the “real world”? A systematic review

10.1016/j.euo.2023.05.002 · 2023 · External reference

BRD4 and cancer: going beyond transcriptional regulation

10.1186/s12943-018-0915-9 · 2018 · External reference

Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target

10.3389/fonc.2024.1309687 · 2024 · External reference

Hallmarks of cancer: new dimensions

10.1158/2159-8290.cd-21-1059 · 2022 · External reference

Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer

10.3892/ijo.2021.5270 · 2021 · External reference

Pediatric acute lymphoblastic leukemia

10.3324/haematol.2020.247031 · 2020 · External reference

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

10.1186/s13045-020-00885-3 · 2020 · External reference

Resistance to antibody-drug conjugates: a review

10.1016/j.apsb.2024.12.036 · 2024 · External reference

Precision medicine review: rare driver mutations and their biophysical classification

10.1007/s12551-018-0496-2 · 2019 · External reference

Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review

10.2147/jbm.s382090 · 2023 · External reference

The promise of targeted therapy: cancer drugs become more specific

10.3949/ccjm.71.7.551 · 2004 · External reference

Chimeric antigen receptor T-cell therapy in cancer: a critical review

10.2174/2589977515666230220092125 · 2023 · External reference

Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer

10.1016/j.molcel.2020.04.027 · 2020 · External reference

Development, efficacy and side effects of antibody-drug conjugates for cancer therapy

10.3892/mco.2023.2643 · 2023 · External reference

Advantages and research progress of three-dimensional culture systems for lung cancer drug screening

10.3892/ol.2026.15702 · 2026 · External reference

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer

10.3892/or.2020.7851 · 2020 · External reference

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer

10.3892/or.2022.8293 · 2022 · External reference

Application of multivalent aptamers in tumor diagnosis, analysis and therapy

10.3892/ol.2025.15071 · 2025 · External reference

T lymphocyte-related immune response and immunotherapy in gastric cancer

10.3892/ol.2024.14670 · 2024 · External reference